UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ARGENTUM PHARMACEUTICALS LLC Petitioner,

v.

ALLERGAN, INC. Patent Owner.

Case IPR2016-01232 Patent 8,629,111

Mailed: July 7, 2016

Before Amy Kattula, Trial Paralegal

DOCKF

NOTICE OF FILING DATE ACCORDED TO PETITION AND TIME FOR FILING PATENT OWNER PRELIMINARY RESPONSE

The petition for *inter partes* review filed in the above proceeding has been accorded the filing date of June 22, 2016.

Patent Owner may file a preliminary response to the petition no later than three months from the date of this notice. The preliminary response is limited to setting forth the reasons why the requested review should not be instituted. Patent Owner may also file an election to waive the preliminary response to expedite the proceeding. For more information, please consult the Office Patent Trial Practice Guide, 77 Fed. Reg. 48756 (Aug. 14, 2012), which is available on the Board Web site at http://www.uspto.gov/PTAB.

Patent Owner is advised of the requirement to submit mandatory notice information under 37 C.F.R. § 42.8(a)(2) within 21 days of service of the petition.

The parties are encouraged to use the heading on the first page of this Notice for all future filings in the proceeding.

The parties are advised that under 37 C.F.R. § 42.10(c), recognition of counsel *pro hac vice* requires a showing of good cause. The parties are authorized to file motions for *pro hac vice* admission under 37 C.F.R. § 42.10(c). Such motions shall be filed in accordance with the "Order -- Authorizing Motion *for Pro Hac Vice* Admission" in Case IPR2013-00639, Paper 7, a copy of which is available on the Board Web site under "Representative Orders, Decisions, and Notices."

The parties are reminded that unless otherwise permitted by 37 C.F.R. § 42.6(b)(2), all filings in this proceeding must be made electronically in the Patent Review Processing System (PRPS), accessible from the Board Web site at <u>http://www.uspto.gov/PTAB</u>. To file documents, users must first obtain a user ID and password by registering with PRPS. Information regarding how to register with and use PRPS is available at the Board Web site.

If there are any questions pertaining to this notice, please contact Amy Kattula at 571-272-5826 or the Patent Trial and Appeal Board at 571-272-7822. Case IPR2016-01232 Patent 8,629,111

PETITIONER:

Matthew Dowd matthewdowd@andrewskurth.com

John Murray johnmurray@andrewskurth.com

PATENT OWNER:

Allergan, Inc. 2525 Dupont Drive, T2-7H Irvine, CA 92612-1599

NOTICE CONCERNING ALTERNATIVE DISPUTE RESOLUTION (ADR)

The Patent Trial and Appeal Board (PTAB) strongly encourages parties who are considering settlement to consider alternative dispute resolution as a means of settling the issues that may be raised in an AIA trial proceeding. Many AIA trials are settled prior to a Final Written Decision. Those considering settlement may wish to consider alternative dispute resolution techniques early in a proceeding to produce a quicker, mutually agreeable resolution of a dispute or to at least narrow the scope of matters in dispute. Alternative dispute resolution has the potential to save parties time and money.

Many non-profit organizations, both inside and outside the intellectual property field, offer alternative dispute resolution services. Listed below are the names and addresses of several such organizations. The listings are provided for the convenience of parties involved in cases before the PTAB; the PTAB does not sponsor or endorse any particular organization's alternative dispute resolution services. In addition, consideration may be given to utilizing independent alternative dispute resolution firms. Such firms may be located through a standard keyword Internet search.

CPR	AMERICAN	AMERICA	WORLD	AMERICAN
INSTITUTE	INTELLECT	Ν	INTELLEC	BAR
FOR	UAL	ARBITRA	TUAL	ASSOCIATI
DISPUTE	PROPERTY	TION	PROPERTY	ON
RESOLUTIO	LAW	ASSOCIAT	ORGANIZA	(ABA)
Ν	ASSOCIATI	ION (AAA)	TION	
	ON (AIPLA)		(WIPO)	
Telephone:	Telephone:	Telephone:	Telephone:	Telephone :
(212) 949-	(703) 415-	(212) 484-	41 22 338	(202) 662-
6490	0780	3266	9111	1000
Fax: (212)	Fax: (703)	Fax: (212)	Fax: 41 22	
949-8859	415-0786	307-4387	733 5428	N/A
	241 18th		34, chemin	1050
575 Lexington	Street, South,	140 West	des	Connecticut
Ave	Suite 700	51st Street	Colombettes	Ave, NW
New York,	Arlington, VA		CH-1211	Washington
NY 10022	22202	New York,	Geneva 20,	D.C. 20036
		NY 10020	Switzerland	

Case IPR2016-01232 Patent 8,629,111

www.cpradr.o		www.adr.or		www.american
rg	www.aipla.org	g	www.wipo.int	bar.org

If parties to an AIA trial proceeding consider using alternative dispute resolution, the PTAB would like to know whether the parties ultimately decided to engage in alternative dispute resolution and the reasons why or why not. If the parties actually engage in alternative dispute resolution, the PTAB would be interested to learn what mechanism (e.g., arbitration, mediation, etc.) was used and the general result. Such a statement from the parties is not required but would be helpful to the PTAB in assessing the value of alternative dispute resolution to parties involved in AIA trial proceedings. To report an experience with ADR, please forward a summary particulars following address: of the to the email PTAB ADR Comments@uspto.gov